Baillie Gifford & CO Crispr Therapeutics Ag Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
A detailed history of Baillie Gifford & CO transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Baillie Gifford & CO holds 364,768 shares of CRSP stock, worth $14.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
364,768
Previous 405,425
10.03%
Holding current value
$14.5 Million
Previous $21.9 Million
21.72%
% of portfolio
0.01%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding CRSP
# of Institutions
489Shares Held
57.9MCall Options Held
1.1MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$315 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$298 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$119 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$118 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$118 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.1B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....